

## A Randomized, Double-Blind, Multicenter, Placebo-Controlled Phase 3 Study with Open-Label Period to Evaluate the Efficacy and Safety of Inebilizumab in Adults with Myasthenia Gravis

**Status:** Recruiting

### Eligibility Criteria

This study is NOT accepting healthy volunteers

### Conditions & Interventions

**Conditions:**

Myasthenia Gravis, Rare Diseases

**Keywords:**

Clinics and Surgery Center (CSC), Myasthenia Gravis

### More Information

**Description:** This is a randomized, double-blind, placebo-controlled, parallel-group study with an optional open-label extension testing the safety and efficacy of inebilizumab in participants with Myasthenia Gravis.

**Contact(s):** Emily Harper - harpe442@umn.edu

**Principal Investigator:** Georgios Manousakis

**Phase:** Phase III

**IRB Number:** STUDY00010270

**System ID:** NCT04524273

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.